BA.2.75 is an emerging omicron variant that has been classed as a variant of interest by the WHO. ACROBiosystems has developed a huge range of antigen products, including Spike trimers and nucleocapsid proteins to help with research into the omicron variant.
The number of COVID-19 cases is currently increasing both globally and in the country due to the recent rapid spread of the Omicron variant, according to information given by the General Department of Preventive Medicine.
COVID-19-related hospitalizations in Colorado fell this week after nearly two months of plateau, and health officials in the state are urging uptake of treatments to prevent severe disease.
In this article, ACROBiosystems discusses BA.2.75, a newly emerging SARS-CoV-2 variant with surprising transmission speed, and the potential ramifications this has against the ongoing fight against COVID-19.
The first case of Covid-19 attributed to a new antibody-avoiding subvariant, BA.2.75, has been detected in Thailand, but experts do not foresee it causing serious outbreaks, according to the Centre for Medical Genomics.